Overactive Bladder Management

Initial Evaluation and Diagnosis

• A comprehensive medical history with assessment of bladder symptoms should be performed in all patients with overactive bladder (OAB) to guide treatment, according to the American Urological Association 1, 2
• Physical examination is a crucial part of the initial evaluation for patients with OAB to identify any underlying conditions that may be contributing to their symptoms 1, 2
• Urinalysis should be conducted to exclude microhematuria and infection in patients with OAB, as recommended by urological guidelines 1, 2
• Post-void residual (PVR) measurement is indicated in patients with concomitant emptying symptoms, history of urinary retention, enlarged prostate, neurologic disorders, prior incontinence or prostate surgery, or long-standing diabetes, based on evidence from urological studies 3, 4

First-Line Treatment: Behavioral Therapies

• Behavioral therapies, such as bladder training, fluid management, and dietary modifications, should be offered as the first step in managing all patients with OAB, due to their excellent safety profile and lack of drug interactions, as supported by the American Urological Association 5, 6
• Fluid management, including optimizing fluid intake throughout the day, is a recommended behavioral intervention for patients with OAB, according to urological guidelines 5, 6
• Dietary modifications, such as avoiding bladder irritants, are suggested as part of first-line treatment for OAB, based on evidence from urological research 5, 6
• Physical activity and exercise can improve overall bladder function in patients with OAB, as recommended by urological guidelines 5, 6

Pharmacologic Treatment Options

• Beta-3 adrenergic agonists, such as mirabegron, are typically preferred over antimuscarinic medications for the treatment of OAB due to their lower cognitive risk, as recommended by the American Urological Association 5, 4
• Antimuscarinic medications can be considered for patients with OAB who have failed behavioral therapies, but their use should be cautious in patients with cognitive impairment risk, based on evidence from urological studies 5, 4

Incontinence Management Strategies

• Absorbent products, barrier creams, and external collection devices can be discussed as management strategies for patients with urgency urinary incontinence, as recommended by urological guidelines 6, 7

Treatment Approach

• Treatment should be chosen based on shared decision-making, considering the patient's values, preferences, and treatment goals, as recommended by the American Urological Association 6, 8
• The success of behavioral therapies depends heavily on patient acceptance, adherence, and compliance, emphasizing the importance of patient education and support, based on evidence from urological research 5, 6

Treatment Options for Overactive Bladder Syndrome

Introduction to Treatment

• The optimal treatment approach for overactive bladder syndrome (OAB) follows a stepwise algorithm beginning with behavioral therapies as first-line treatment, followed by pharmacologic options as second-line treatment, and progressing to more invasive procedures for refractory cases 9

Pharmacologic Management

• Antimuscarinic medications, such as darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium, are options for OAB treatment, but should be used with caution in patients with narrow-angle glaucoma, impaired gastric emptying, history of urinary retention, or cognitive impairment 9
• Post-void residual greater than 250-300 mL warrants caution when using antimuscarinic medications 9

Combination Therapy and Treatment Adjustments

• Behavioral therapies may be combined with pharmacologic management to optimize symptom control 9
• Initiating behavioral and drug therapy simultaneously may improve outcomes, including frequency, voided volume, incontinence, and symptom distress 9
• If inadequate symptom control or unacceptable adverse events occur with one antimuscarinic medication, consider dose modification 9
• If inadequate symptom control or unacceptable adverse events occur with one antimuscarinic medication, consider switching to a different antimuscarinic 9
• If inadequate symptom control or unacceptable adverse events occur with one antimuscarinic medication, consider switching to a beta-3 adrenergic agonist 9

Third-Line Treatment

• Intradetrusor onabotulinumtoxinA injections are an option for patients who fail behavioral and pharmacologic interventions, but patients must be willing to perform clean intermittent self-catheterization if needed 9
• Peripheral tibial nerve stimulation (PTNS) is an option for patients who fail behavioral and pharmacologic interventions, but requires frequent office visits 9
• Sacral neuromodulation (SNS) is an option for patients who fail behavioral and pharmacologic interventions 9

Special Considerations

• Caution should be exercised when prescribing antimuscarinics or beta-3 adrenergic agonists to patients with post-void residual 250-300 mL 9

Treatment for Overactive Bladder with Dosages

First-Line Treatment: Behavioral Therapies

• The American Urological Association recommends starting all patients with behavioral therapies immediately, including bladder training and delayed voiding, to practice postponing urination when urgency occurs, gradually extending intervals between voids, with equal effectiveness to antimuscarinics but zero risk 10, 11
• Fluid management, reducing total daily fluid intake by 25%, decreases frequency and urgency, with particular attention to evening fluid restriction 11
• Caffeine and alcohol avoidance eliminates bladder irritants from the diet 10
• Pelvic floor muscle training, strengthening exercises for urge suppression and improved bladder control, is recommended 11
• Weight loss, even 8% reduction in obese patients, reduces urgency incontinence episodes by 42% 11

Second-Line Treatment: Pharmacologic Options

• The American Urological Association recommends mirabegron 25-50 mg daily as the preferred pharmacologic option over antimuscarinics due to lower cognitive risk 10
• Antimuscarinics, such as darifenacin, fesoterodine, oxybutynin, solifenacin, and tolterodine, are alternative options when beta-3 agonists fail or are contraindicated, with no single antimuscarinic showing superior efficacy over others 10, 11
• Critical antimuscarinic contraindications and precautions include narrow-angle glaucoma, impaired gastric emptying, history of urinary retention, and post-void residual >250-300 mL 11

Treatment Adjustments for Inadequate Response

• Allow 8-12 weeks to assess efficacy before changing therapy, and consider dose modification, switching to a different antimuscarinic, or adding combination therapy if inadequate symptom control or intolerable side effects occur 11

Essential Monitoring

• Measure post-void residual before starting antimuscarinics in patients with emptying symptoms, history of retention, enlarged prostate, neurologic disorders, prior incontinence/prostate surgery, or long-standing diabetes 10
• Annual follow-up to assess treatment efficacy and symptom changes is recommended 10

Patient Education for Overactive Bladder

Core Educational Message: Shared Decision-Making and Treatment Menu

• Patients with OAB should be educated that treatment is no longer a rigid stepwise progression, but rather a menu of options they can select from—including multiple categories simultaneously—based on their individual preferences, side effect tolerance, and lifestyle needs, as recommended by the American Urological Association 12, 13

Essential Educational Components About OAB

• Patients should understand that OAB significantly affects quality of life, and many suffer for extended periods before seeking help—emphasizing that treatment is available and effective, according to the American Urological Association 13

First-Line Education: Behavioral Therapies

• All patients should be educated about timed voiding, which involves practicing scheduled urination at regular intervals to retrain the bladder, gradually extending time between voids, as recommended by the American Urological Association 12
• Patients should be taught urgency suppression techniques, such as stopping, sitting down, performing pelvic floor muscle contractions, using distraction or relaxation techniques, and waiting for the urgency to pass before walking calmly to the bathroom, as recommended by the American Urological Association 12
• Patients should be educated about bladder irritant avoidance, including eliminating or reducing caffeine and alcohol consumption, as these directly irritate the bladder, according to the American Urological Association 12

Incontinence Management Strategies Education

• Patients should be educated about symptom management products, such as pads, liners, absorbent underwear, and barrier creams, to prevent urine dermatitis and maintain quality of life, as recommended by the American Urological Association 12
• Patients should understand that these products manage symptoms but do not treat the underlying OAB condition—they should be used alongside, not instead of, active treatment, according to the American Urological Association 12

Comorbidity Optimization Education

• Patients should understand that managing related conditions, such as pelvic organ prolapse, can significantly improve OAB symptoms, as recommended by the American Urological Association 13

Monitoring and Follow-Up Education

• High-risk patients should be educated about post-void residual measurement, which is required before starting antimuscarinics, as recommended by the American Urological Association 12

Telemedicine Option

• Patients can be educated that initial evaluation via telemedicine is acceptable, though urinalysis should be obtained at a local laboratory, and physical examination/PVR measurement will be limited, as recommended by the American Urological Association 12, 13
• Non-responders to initial telemedicine treatment should have in-office evaluation with physical exam, PVR measurement, and urinalysis, according to the American Urological Association 12, 13

Treatment of Overactive Bladder

Introduction to Overactive Bladder Treatment

• The American Urological Association recommends that patients at risk for gastric emptying problems require gastroenterology clearance before starting antimuscarinics, and those at risk for urinary retention require urology clearance 14
• Antimuscarinics are contraindicated in patients using solid oral potassium chloride due to increased potassium absorption risk 14

Pharmacologic Therapy

• The dosage adjustments for hepatic impairment are as follows: Child-Pugh Class A (mild): Start 25 mg, maximum 50 mg daily, Child-Pugh Class B (moderate): Start 25 mg, maximum 25 mg daily, Child-Pugh Class C (severe): Not recommended 14
• Patients with severe refractory OAB symptoms should be evaluated by a urologist before proceeding to advanced therapies, which present increasing risk that must be balanced with potential efficacy 14

Third-Line Treatments for Refractory Cases

• Sacral Neuromodulation (SNS) is an FDA-approved third-line treatment for severe refractory OAB symptoms, with all measured parameters including quality of life showing improvement, but improvement dissipates if treatment ceases 14
• Peripheral Tibial Nerve Stimulation (PTNS) is a third-line option requiring frequent office visits, with a standard protocol of 30 minutes of stimulation once weekly for 12 weeks, and improvements maintained with ongoing treatment 14
• Intradetrusor OnabotulinumtoxinA Injections are a third-line option for carefully selected patients refractory to first- and second-line treatments, with a critical requirement that the patient must be able and willing to return for frequent PVR evaluation and perform self-catheterization if necessary 14

Comorbidity Optimization

• Treating conditions that affect OAB severity, such as constipation, can improve symptoms 14
• Tobacco cessation is also important for optimizing OAB symptoms 14